Xalkori by Pfizer effective in treating NSCLC, a rare type of lung cancer

September 29, 2014 4:52 AM

13 0

Dr. Alice Shaw, the lead investigator reported that this clinical trial is the first solid study which establishes crizotinib’s activity in victims of lung cancer who are tested positive for ROS1 and also confirms ROS1 as an authentic therapeutic target in such patients.

The study involved around 50 individuals who were diagnosed with NSCLC with a mutation in ROS1 gene. Out of the 50, shrinkage in tumor size was seen in 36 patients who consumed the drug. A remarkable conclusion was made that 72 percent of the people were benefitted from the Pfizer medication through...

Read more

To category page